medigraphic.com

2015, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (6)

Features of Guillain-Barre syndrome in adults: results of a university hospital

de la O-Peña D, Robles-Figueroa M, Chávez-Peña Q, Bedolla-Barajas M

Language: Spanish
References: 35
Page: 678-685
PDF size: 326.88 Kb.


ABSTRACT

Background: Guillain-Barré syndrome (GBS) has a cosmopolitan distribution. Its course is usually mild and tends to limit itself, but in severe cases it can cause death. The aim of this article is to describe the characteristics of a group of adults with GBS diagnosed and treated at a university hospital.
Methods: All cases of GBS that occurred between January 1, 2005 to December 31, 2009 were analyzed. The clinical records were reviewed through the implementation of a structured survey that included the following sections: patient identification, clinical data, history of infection, season of occurrence, rates of electrophysiological variants, and lethality.
Results: A total of 45 patients were included; the male to female ratio was 1.4: 1 and the mean age was 48.2 ± 16.0 years. The season with the highest number of cases was the summer. History of intestinal infection was present in 40 % of patients, and respiratory infection in 24.4%. The lethality associated with GBS was 11.1 % (95 % CI, 4.4-23.9), fatal cases occurred in patients older than the survivors (65.2 ± 15.0 versus 46.0 ± 14.9, p = 0.01). The most common variant was acute motor axonal neuropathy (64.4 %); there were four cases of Miller Fisher syndrome.
Conclusions: The most common electromyographic variant of GBS was acute motor axonal neuropathy. The highest number of cases was observed during the summer season.


REFERENCES

  1. Asbury AK. New concepts of Guillain-Barré syndrome. J Child Neurol. 2000; 15 (3): 183-91.

  2. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990; 27 Suppl: S21- 4.

  3. Piñol-Ripoll G, Larrodé Pellicer P. Características del síndrome de Guillain-Barré en el área III de salud de la Comunidad Autónoma de Aragón. An Med Interna. 2008; 25(3):108-12.

  4. Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry. 1997; 63(4):494-500.

  5. Arami MA, Yazdchi M, Khandaghi R. Epidemiology and characteristics of Guillain-Barré syndrome in the northwest of Iran. Ann Saudi Med. 2006; 26(1):22-7.

  6. Monroy-Guerrero J, Nuñez-Orozco L. Syndrome de Landry-Guillain-Barré-Strohl. Casuística en un hospital de concentración. Rev Mex Neuroci. 2005; 6:372- 83.

  7. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain Barré syndrome. N Engl J Med. 1995; 333 (21):1374-79.

  8. Owagara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000; 48 (4); 624-31.

  9. Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y. Guillain-Barré Syndrome- A classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol. 2012; 42 (2):121-30.

  10. Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010; 10(9):643-51.

  11. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23(4):347-53.

  12. Van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, Van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol. 2007; 6(7):589-94.

  13. Chio, A, Cocito, D, Leone, M, Giordana MT, Mora G et Al. Guillain-Barre syndrome: a prospective, population-based Incidence and outcome survey. Neurology 2003; 60 (7):1146- 50.

  14. Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007; 130(Pt 9):2245-57.

  15. Lawn ND, Wijdicks EF. Fatal Guillain-Barre syndrome. Neurology. 1999; 52(3):635-8.

  16. Ropper AH. The Guillain Barré síndrome. N Engl J Med 1992. 326 (17): 1130-1136.

  17. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain Barré síndrome. Neurology. 1997; 48 (2):328-31.

  18. Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs BC, et al. Pain in Guillain Barre Syndrome: a long term follow up study. Neurology. 2010; 75(16):1439-47.

  19. Alshekhlee A, Hussain Z, Sultan B, Karitji B. Guillain Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008; 70(18):1608-13.

  20. Zochodne DW. Autonomic involvement in Guillain Barre syndrome: a review. Muscle Nerve 1994; 17(10):1145-55.

  21. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118 (Pt 3):597-605.

  22. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, et al. Pathology of the motorsensory axonal Guillain-Barré Syndrome. Ann Neurol.1996;39(1)17-28.

  23. Lo YL. Clinical and inmunological spectrum of the Miller Fisher syndrome. Muscle Nerve; 2007; 36(5):615-27.

  24. Instituto Nacional de Estadistica y Geografía. Acceso 03 de mayo de 2015. Disponible en: http://www3.inegi. org.mx/sistemas/mexicocifras/default.aspx?e=14

  25. National Institute of Neurological Disorders and Stroke. Acceso 27 de octubre de 2012. Disponible en: http://www.ninds.nih.gov/disorders/gbs/gbs.htm

  26. Melano-Carranza E, Carrillo-Maravilla E, Gulias- Herrero A, Avila-Funes JA. Sindrome de Guillain- Barre en el anciano: un estudio retrospectivo. Arch Neurocien 2004; 2:119-122.

  27. Zúñiga-González EA, Rodríguez-de la Cruz A, Millán-Padilla J. Electrophysiological subtypes of Guillain-Barré syndrome in Mexican adults. Rev Med Inst Mex Seguro Soc. 2007 Sep-Oct; 45(5):463-8.

  28. Hughes RAC, Rees JH. Clinical and epidemiologic features of Guillian-Barré syndrome. J Infect Dis 1997; 176 (suppl 2): S92-S98.

  29. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31: 578-85.

  30. Tellez-Zenteno JF, Jacinto-Tinajero JC, Avila- Fuentes A. Sindrome de Guillain-Barré. Experiencia en un hospital de tercer nivel. Rev Invest Clin. 2001; 53(4):311-4.

  31. Nachamkin I, Arzate-Barbosa P, Ung H. Patterns of Guillain-Barré syndrome in children: Results from a Mexican population. Neurology October 23, 2007 69:1665-71.

  32. Kissel JT, Cornblath DR, Mendell JR. Guillain- Barre syndrome. In: Diagnosis and management of peripheral nerve disorders, Oxford University Press, New York 2001.

  33. Nobuhiro Yuki, Hans-Peter Hartung. Guillain–Barré Syndrome. N Engl J Med 2012; 366:2294-2304.

  34. Nishimoto Y, Odaka M, Hirata K, Yuki N.Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol. 2004 Mar; 148 (1-2):200-5.

  35. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012; 78 (13):1009-15.




2020     |     www.medigraphic.com